Pharmacologic treatments for covid-19 patients
Methods
Protocol amendment:
As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.
meta-COVID
Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:
Treatment comparisons
Create and download your forest plots with the most up-to-date data here Forest plots
Display new or updated analyses
Your research: comparisons updated with new studies
Access the forest plots for the 15 treatment comparisons .
Anti-virals (3 comparisons)
Other antimicrobials (antibiotics, antimalarials, antiparasitics) (1 comparisons)
Kinase inhibitor (1 comparisons)
Corticosteroids (1 comparisons)
Monoclonal antibodies (4 comparisons)
Immunosupressant (1 comparisons)
Convalescent plasma (1 comparisons)
Antithrombotic (antiplatelet, anticoagulant, thrombolytic drug) (2 comparisons)
Search studies
General characteristics of primary studies
Go to page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47
| Page: 1 / Sorted by: Most recent ↓ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
| Treatment 1 | Treatment 2 | |||||||
New NCT04425915COPLA-II trial Bajpai M, BMJ Open, 2022 Full text Commentary Commentary |
No specific funding |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in India. | N=400 |
Some concerns Details |
|
New NCT04438980 ; EudraCT 2020-001827-15 CORTIVID Les I, Front Med , 2022 Full text Commentary Commentary |
Public/non profit |
Intravenous Methylprednisolone pulse |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate) admitted to 2 centers in Spain. | N=72 |
Low Details |
|
New NCT04405310 Fernandez-Sanchez V, Research Square, 2022 Full text Commentary Commentary |
Public/non profit |
Convalescent plasma |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to two centers in Mexico | N=43 |
Some concerns Details |
|
New NCT04505774ACTIV-4a Berger JS, JAMA, 2022 Full text Commentary Commentary |
Public/non profit |
Therapeutic anticoagulant + P2Y12 Inhibitor |
Therapeutic anticoagulant |
RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 60 centers in Brazil, Italy, Spain and USA. | N=562 |
Some concerns Details |
|
New CTRI/2020/07/026835 Nair PR, Respir Care, 2021 Full text Commentary |
Public/non profit |
Noninvasive ventilation |
High flow nasal cannula |
RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in India. | N=109 |
Some concerns Details |
|
| NCT04356495, EudraCT 2020-001435-27 COVERAGE Duvignaud A, Clin Microbiol Infect, 2022 Full text Commentary |
Public/non profit |
Ciclesonide |
Standard care |
RCT | Outpatients with confirmed COVID-19 (symptomatic) treated by 14 centers in France | N=217 |
Some concerns Details |
|
| NCT04351243 BREATHE Criner GJ , Am J Respir Crit Care Med, 2022 Full text Commentary |
Private |
Gimsilumab |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 21 centers in the USA. | N=227 |
Some concerns Details |
|
| NCT04673162 ; EudraCT 2020-004323-16 Salvarani C, Eur Respir J, 2022 Full text Commentary |
No specific funding |
Methylprednisolone |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 19 centers in Italy. | N=304 |
Low Details |
|
| IRCT20200506047323N3 Hassaniazad M, J Med Virol, 2022 Full text Commentary |
Public/non profit |
Favipiravir |
Lopinavir + Ritonavir |
RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. | N=66 |
Some concerns Details |
|
| IRCT20151227025726N14 Tabarsi P, Iran J Pharm Res, 2021 Full text Commentary Commentary |
Public/non profit |
Favipiravir |
Lopinavir + Ritonavir |
RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. | N=62 |
Some concerns Details |
|